Skip to main content
SpringerLink
Log in

Mismatched Double-Stranded RNA

Ampligen®, Oragen®, Polyi:Polyc12u

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. McMahon D, Winkelstein A, Huang X-L, Armstrong J, Pazin G, et al. Acute reactions associated with the infusion of ampligen. AIDS 6: 235–236, Feb 1992

    PubMed  CAS  Google Scholar 

  2. Armstrong JA, McMahon D, Huang X-L, Pazin GJ, Gupta P, et al. A phase I study of ampligen in human immunodeficiency virus-infected subjects. Journal of Infectious Diseases 166: 717–722, Oct 1992

    Article  PubMed  CAS  Google Scholar 

  3. Hendrix CW, Margolick JB, Petty BG, Markham RB, Nerhood L, et al. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers. Antimicrobial Agents and Chemotherapy 37: 429–435, Mar 1993

    Article  PubMed  CAS  Google Scholar 

  4. Gillespie D, Hubbell HR, Carter WA, Midgette P, Elsasser W, et al. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements. In Vivo 8: 375–381, May-Jun 1994. USA

    PubMed  CAS  Google Scholar 

  5. Thompson KA, Strayer DR, Salvato PD, Thompson CE, Klimas N, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC(12)U in the treatment of HIV infection. European Journal of Clinical Microbiology and Infectious Diseases 15: 580–587, Jul 1996

    Article  CAS  Google Scholar 

  6. Buzaid AC, Strayer DR, Witman PA, et al. Phase I/II study of poly I:polyC(12)U (Ampligen Rm) shows activity against metastatic melanoma. Proceedings of the American Society of Clinical Oncology 13: 399, Mar 1994

    Google Scholar 

  7. Essey RJ, McDougall BR, Robinson WE. Mismatched doublestranded RNA (PolyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistantHIV-1 in vitro. Antiviral Research 51: 189–202, Sep 2001

    Article  PubMed  CAS  Google Scholar 

  8. Niu J, Wang Y, Dixon R, et al. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Research 21: 155–171, Jun 1993

    Article  PubMed  CAS  Google Scholar 

  9. Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clinical Infectious Diseases 18 (Suppl 1): 96–104, Jan 1994

    Article  Google Scholar 

  10. Ushijima H, Tsiapalis CM, Daum T, Schröder HC, Matthes E, et al. Synergistic anti-human immunodeficiency viral (HIV- 1) effect of the immunomodulator ampligen (mismatched double-stranded RNA) with inhibitors of reverse transcriptase and HIV-1 regulatory proteins. Antiviral Chemistry and Chemotherapy 4: 315–321, No. 6, 1993

    CAS  Google Scholar 

  11. O’Marro SD, Armstrong JA, Asuncion C, Gueverra L, Ho M. The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro. Antiviral Research 17: 169–177, Feb 1992

    Article  PubMed  Google Scholar 

  12. Ablashi DV, Berneman Z, Strayer DR, et al. Poly(I). poly(C12U) inhibits in vitro replication of human herpesvirus type 6. Clinical Infectious Diseases 18 (Suppl1): 113, Jan 1994

    Google Scholar 

  13. Ablashi DV, Berneman ZN, Williams M, Strayer DR, Kramarsky B, et al. Ampligen inhibits human herpesvirus-6 in vitro. In Vivo 8: 587–591, Jul-Aug 1994

    PubMed  CAS  Google Scholar 

  14. Konishi K, Mukoyama A, Müller WEG, et al. Effect of poly(I). poly(C12U) (Ampligen) on enteric virus (rotavirus, poliovirus and Coxsackie B3 virus) infections. Letters in Applied Microbiology 19: 386–390, Nov 1994

    Article  CAS  Google Scholar 

  15. Ijichi K, Mitamura K, Ida S, et al. Comparison of antiviral effects of mismatched double-stranded RNA and 1-(2′deoxy-2′-fluoro-beta-D-arabinofuranosyl) -5-methyl-uracil (D-FAMU) against duck hepatitis B virus in vitro. Antiviral Chemistry and Chemotherapy 8: 537–540, Nov 1997

    CAS  Google Scholar 

  16. Hemispherx Biopharma Inc. New study indicates benefits of Ampligen (R) in treatment of severe CFS. Media Release.: [2 pages], 13 Sep 1999. Available from: URL: http://www.hemispherx.com

    Google Scholar 

  17. O’Brien CB, Garcia G, Henzel B, et al. Ampligen treatment of chronic hepatitis B. Gastroenterology 106 (Suppl): 952, Apr 1994

    Google Scholar 

  18. Carter WA, Ventura D, Shapiro DE, Strayer DR, Gillespie DH, et al. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease. International Journal of Immunopharmacology 13 (Suppl 1): 69–76, 1991

    Article  PubMed  CAS  Google Scholar 

  19. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clinical Infectious Diseases 18 (Suppl1): 88–95, Jan 1994

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mismatched Double-Stranded RNA. Drugs R&D 3, 132–138 (2002). https://doi.org/10.2165/00126839-200203020-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203020-00016

Keywords

Search

Navigation